PartnershipApr 7, 2026, 07:06 AM
GT Biopharma Enters Clinical Trial Agreement with University of Minnesota for GTB-5550 Cancer Therapy
AI Summary
GT Biopharma has entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota to conduct a Phase 1a/1b clinical trial of GTB-5550, a TriKE® (Tri-Specific Killer Engager) therapy targeting B7-H3 in advanced solid tumors. The agreement outlines the terms for the study, including GT Biopharma's support through funding and the Study Drug, and the University's responsibilities as the IND sponsor and investigator.
Key Highlights
- GT Biopharma will provide the Study Drug (GTB-5550) and funding for the clinical trial.
- The University of Minnesota, through Dr. Nicholas Zorko, will act as the sponsor-investigator for the trial.
- The trial will evaluate GTB-5550 in patients with select advanced solid tumors that have failed prior therapy.
- GTB-5550 is a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE®).
Price Impact
More from GTBP